Abemaciclib is synergistic with doxorubicin in osteosarcoma pre-clinical models via inhibition of CDK4/6–Cyclin D–Rb pathway

Combination of CDK4/6 and mTOR Inhibitors Suppressed Doxorubicin-resistant Osteosarcoma in a Patient-derived Orthotopic Xenograft Mouse Model: A Translatable Strategy for Recalcitrant Disease

(2021) HIROMICHI OSHIRO et al.   ANTICANCER RESEARCH

A comprehensive review on time-tested anticancer drug doxorubicin

(2021) Sruthi Sritharan et al.   LIFE SCIENCES

Epidemiology and Risk Factors of Osteosarcoma

(2020) Leissan R. Sadykova et al.   CANCER INVESTIGATION

Tumor Milieu Controlled by RB Tumor Suppressor

(2020) Shunsuke Kitajima et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Osteosarcoma: A comprehensive review of management and treatment strategies

(2020) Farzaneh Jafari et al.   Annals of Diagnostic Pathology

Retinoblastoma Tumor Suppressor Protein Roles in Epigenetic Regulation

(2020) Frederick Guzman et al.   Cancers

Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences

(2020) C. Louwrens Braal et al.   DRUGS

Methotrexate, doxorubicin, and cisplatinum regimen is still the preferred option for osteosarcoma chemotherapy

(2019) Dapeng Yu et al.   MEDICINE

Combining CDK4/6 inhibitors ribociclib and palbociclib with cytotoxic agents does not enhance cytotoxicity

(2019) Dan Jin et al.   PLoS One

Abemaciclib, a Selective CDK4/6 Inhibitor, Enhances the Radiosensitivity of Non–Small Cell Lung CancerIn VitroandIn Vivo

(2018) Sarwat Naz et al.   CLINICAL CANCER RESEARCH

Profile of abemaciclib and its potential in the treatment of breast cancer

(2018) James M Martin et al.   OncoTargets and Therapy

Novel insights and therapeutic interventions for pediatric osteosarcoma

(2017) Leo Kager et al.   Future Oncology

CDK4/6 Inhibitors Sensitize Rb-positive Sarcoma Cells to Wee1 Kinase Inhibition through Reversible Cell-Cycle Arrest

(2017) Ashleigh M. Francis et al.   MOLECULAR CANCER THERAPEUTICS

Targeting CDK4/6 in patients with cancer

(2016) Erika Hamilton et al.   CANCER TREATMENT REVIEWS

Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma

(2016) Julien Bollard et al.   GUT

Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors

(2016) A. Patnaik et al.   Cancer Discovery

Palbociclib (PD0332991)—a Selective and Potent Cyclin-Dependent Kinase Inhibitor

(2016) Amy S. Clark et al.   JAMA Oncology

Molecular Pathways: Targeting the Cyclin D-CDK4/6 Axis for Cancer Treatment

(2015) T. VanArsdale et al.   CLINICAL CANCER RESEARCH

Targeting CDK4 and CDK6: From Discovery to Therapy

(2015) C. J. Sherr et al.   Cancer Discovery

Searching for Drug Synergy in Complex Dose–Response Landscapes Using an Interaction Potency Model

(2015) Bhagwan Yadav et al.   Computational and Structural Biotechnology Journal

The Soft Agar Colony Formation Assay

(2014) Stanley Borowicz et al.   Jove-Journal of Visualized Experiments

Signaling through cyclin D-dependent kinases

(2013) Y J Choi et al.   ONCOGENE

CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy

(2012) A. Kathleen McClendon et al.   CELL CYCLE

p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells

(2012) L. Cen et al.   NEURO-ONCOLOGY